Product Information

VYLIBRA 28 TABLET is a generic product labeled by Afaxys Pharma, LLC, priced at $0.1257 per EA under NDC 50102023511. Its NADAC has been published 425 times since May 9, 2018.

VYLIBRA 28 TABLET

norgestimate and ethinyl estradiol
$0.1257per EA

Manufacturer

Afaxys Pharma, LLC

NDC

50102023511

Classification

Generic

Dosage Form

KIT

Last Updated

6/17/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA205449

On Market Since

7/7/2016

Price Statistics

The NADAC for VYLIBRA 28 TABLET has been published 425 times since May 9, 2018, and over the history we have for it it has declined 53.8%. The table below summarizes its recorded NADAC range and movement.

Current price$0.1257 per EA
All-time high$0.2724 (May 16, 2018)
All-time low$0.1011 (Nov 20, 2024)
52-week high$0.1351
52-week low$0.1230
Median price$0.1673
Average price$0.1792
Largest weekly change-21.9% (Nov 20, 2024)
Weeks tracked425
Tracking sinceMay 9, 2018

Price History

1W

0.0%

1M

+0.2%

3M

+1.4%

6M

+2.2%

1Y

-6.9%

3Y

-15.6%

5Y

-40.9%

All

-53.8%

Generic Alternatives

The matcher finds 8 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 8 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 17% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of VYLIBRA 28 TABLET?

The current National Average Drug Acquisition Cost (NADAC) for VYLIBRA 28 TABLET, manufactured by Afaxys Pharma, LLC, is $0.1257 per EA (NDC 50102023511), effective Jun 24, 2026.

How has the price of VYLIBRA 28 TABLET changed over time?

Over the history we have for it, the NADAC for VYLIBRA 28 TABLET has declined 53.8%. It has been tracked across 425 weekly CMS publications since May 9, 2018.

What are the highest and lowest recorded NADAC prices for VYLIBRA 28 TABLET?

Since May 9, 2018, the NADAC for VYLIBRA 28 TABLET has ranged from a low of $0.1011 (Nov 20, 2024) to a high of $0.2724 (May 16, 2018), with a median of $0.1673 per EA.

Are there cheaper alternatives to VYLIBRA 28 TABLET?

Yes. 8 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, TRI-LO-ESTARYLLA TABLET, is $0.1049 per EA — about 17% below VYLIBRA 28 TABLET.

Who manufactures VYLIBRA 28 TABLET?

VYLIBRA 28 TABLET (NDC 50102023511) is labeled by Afaxys Pharma, LLC, and CMS classifies it as a generic product.

Related Drugs

Same classification

No related drugs found.